These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19075484)

  • 1. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension.
    Komiya N; Hirose H; Saisho Y; Saito I; Itoh H
    Int Heart J; 2008 Nov; 49(6):681-9. PubMed ID: 19075484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan.
    Saisho Y; Komiya N; Hirose H
    Diabetes Res Clin Pract; 2006 Nov; 74(2):201-3. PubMed ID: 16737758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of valsartan therapy on protein glycoxidation.
    Monacelli F; Poggi A; Storace D; Durante A; Traverso N; Viviani GL; Odetti P
    Metabolism; 2006 Dec; 55(12):1619-24. PubMed ID: 17142134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
    Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
    Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
    Hollenberg NK; Parving HH; Viberti G; Remuzzi G; Ritter S; Zelenkofske S; Kandra A; Daley WL; Rocha R
    J Hypertens; 2007 Sep; 25(9):1921-6. PubMed ID: 17762658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets).
    Shishido T; Konta T; Nishiyama S; Miyashita T; Miyamoto T; Takasaki S; Nitobe J; Watanabe T; Takeishi Y; Kubota I
    Clin Exp Hypertens; 2011; 33(2):117-23. PubMed ID: 21269062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial.
    Serebruany VL; Pokov AN; Aradi D; Can M; DiNicolantonio J; Kipshidze N; Atar D
    Am J Ther; 2014; 21(6):482-90. PubMed ID: 23698186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.
    Watanabe S; Okura T; Kurata M; Irita J; Manabe S; Miyoshi K; Fukuoka T; Gotoh A; Uchida K; Higaki J
    Clin Exp Hypertens; 2006 Jul; 28(5):451-61. PubMed ID: 16820342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
    Savoia C; Touyz RM; Volpe M; Schiffrin EL
    Hypertension; 2007 Feb; 49(2):341-6. PubMed ID: 17159079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
    Mann J; Julius S
    Blood Press; 1998 May; 7(3):176-83. PubMed ID: 9758088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
    Everett BM; Glynn RJ; Danielson E; Ridker PM;
    Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
    Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
    Thromb Res; 2006; 117(4):385-92. PubMed ID: 15896827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
    Ogawa S; Mori T; Nako K; Kato T; Takeuchi K; Ito S
    Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valsartan prevents neointimal hyperplasia after carotid artery stenting by suppressing endothelial cell injuries.
    Suzuki H; Sano T; Umeda Y; Yamamoto A; Toma N; Sakaida H; Taki W
    Neurol Res; 2015 Jan; 37(1):35-42. PubMed ID: 24938321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
    Yasunari K; Maeda K; Watanabe T; Nakamura M; Yoshikawa J; Asada A
    J Am Coll Cardiol; 2004 Jun; 43(11):2116-23. PubMed ID: 15172423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
    Rajagopalan S; Zannad F; Radauceanu A; Glazer R; Jia Y; Prescott MF; Kariisa M; Pitt B
    Am J Cardiol; 2007 Jul; 100(2):222-6. PubMed ID: 17631074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.